Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes

Trial Profile

Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2019

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DECLARE; DECLARE-TIMI58
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Jun 2019 Results assessing performance of commonly used cardio vascular events risk equations to the outcomes of this trial presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
    • 11 Jun 2019 Results aiming to quantify the implications of renal outcomes from DECLARE-TIMI 58 in terms of direct healthcare costs and resource use presented at the 79th Annual Scientific Sessions of the American Diabetes Association
    • 11 Jun 2019 Results assessing the performance of the UKPDS 82 risk equation in the DECLARE-TIMI 58 population presented at the 79th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top